Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

NCT06417814 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06417814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06417814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
October 4, 2024
Completion date
September 27, 2028
Enrollment
744 (estimated)
Sites
303

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-small cell lung cancer